Top Gainers Technical Data -- Research on First Solar, Oncothyreon, Unilife, and Synthetic Biologics

LONDON, March 20, 2014 /PRNewswire/ --

The US markets saw a negative sentiment on Wednesday, March 19, 2014, with the NASDAQ Composite closing at 4,307.60, down 0.59%, the Dow Jones Industrial Average ending the session at 16,222.17, down 0.70% and the S&P 500 edging 0.61% lower to finish the trading session at 1,860.77. The losses were broad based as all the ten sectors ended the session in negative. A number of stocks saw large movements, including First Solar Inc. (NASDAQ: FSLR), Oncothyreon Inc. (NASDAQ: ONTY), Unilife Corp. (NASDAQ: UNIS), and Synthetic Biologics Inc. (AMEX: SYN). Free technical research on FSLR, ONTY, UNIS, and SYN can be downloaded upon signing up at:

http://www.investor-edge.com/348-register

Shares in First Solar Inc. edged 20.57% higher, finishing Wednesday's session at $69.40, hitting a new 52-week high of $70.99. The stock fluctuated between $56.96 and $70.99 during the session with a trading volume of 30.82 million shares as compared to a three months average volume of 4.00 million shares. Shares in First Solar Inc. have gained 28.45% in the previous three trading sessions and 22.27% in the last three months. The company's shares are traded at a PE ratio of 16.65 and have gone up 27.01% on YTD basis. The S&P 500 Information Technology Sector Index mapped a loss of 0.52% during the trading session and charted up 1.14% in the last one month. Furthermore, the stock is trading at the RSI of 57.82 and above its 50-day and 200-day moving averages of $53.03 and $49.60, respectively. Sign up today to read free research on FSLR at:

http://www.investor-edge.com/348-FSLR-20Mar2014.pdf

Oncothyreon Inc.'s stock closed Wednesday's session at $3.60, which is 6.19% higher than the previous day's closing price of $3.39. A total of 1.94 million shares were traded as compared to a three months average volume of 0.94 million shares. The stock oscillated between $3.19 and $3.62 during the trading session. Oncothyreon Inc.'s shares have surged 24.14% in the last one month, 103.39% in the previous three months and 104.55% on YTD basis. The S&P 500 Health Care Sector Index mapped a loss of 0.37% during the trading session and charted up 8.42% in the previous three months. Moreover, the stock is trading at the RSI of 56.49 and above its 50-day and 200-day moving averages of $2.69 and $2.03, respectively. Sign up today to read free research on ONTY at:

http://www.investor-edge.com/348-ONTY-20Mar2014.pdf

On Wednesday, shares in Unilife Corp. ended the session at $5.74, up 12.55%, hitting a new 52-week high of $5.80. A total of 5.36 million shares were traded as compared to a three months average volume of 1.13 million shares. During the session, the stock traded between $5.05 and $5.80. Unilife Corp.'s shares have advanced 36.67% in the last one month, 38.65% in the previous three months and 30.45% on YTD basis. The S&P 500 Health Care Sector Index mapped a loss of 0.37% during the trading session and charted up 1.70% in the last one month. Further, the stock is trading at the RSI of 66.37 and above its 50-day and 200-day moving averages of $4.47 and $3.66, respectively. Sign up today to read free research on UNIS at:

http://www.investor-edge.com/348-UNIS-20Mar2014.pdf

Synthetic Biologics Inc.'s stock finished Wednesday's session at $3.45, recording a 9.52% gain, after hitting a new 52-week high of $3.64. A total of 5.35 million shares were traded which is above the three months average volume of 1.15 million shares. The stock vacillated between $3.25 and $3.64 during the session. Synthetic Biologics Inc.'s shares have rallied 26.84% in the last one month, 210.81% in the previous three months and 125.49% on YTD basis. The S&P 500 Health Care Sector Index declined 0.37% during the trading session, while the same has gained 1.72% in the previous three trading sessions. Additionally, the stock is trading at the RSI of 70.13 and above its 50-day and 200-day moving averages of $2.28 and $1.72, respectively. Sign up today to read free research on SYN at:

http://www.investor-edge.com/348-SYN-20Mar2014.pdf


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED